The Agreement includes the assets, specialized licensing, operational knowledge, and Australian and New Zealand customers currently served from that facility.
“This is the beginning of a meaningful long-term partnership dedicated to bringing the unique benefits of GMP-certified medical cannabis to patients in Europe,”